Rhumbline Advisers Aadi Bioscience, Inc. Transaction History

Rhumbline Advisers

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 01, 2024	SELL	$1.46 - $2.31 $23,212 - $36,726	-15,899 Reduced 62.63%	9,487 $13,000
Q1 2024 May 09, 2024	BUY	$1.59 - $2.44 $936 - $1,437	589 Added 2.38%	25,386 $59,000
Q3 2023 Nov 09, 2023	BUY	$4.84 - $7.13 $6,045 - $8,905	1,249 Added 5.3%	24,797 $120,000
Q2 2023 Aug 08, 2023	BUY	$6.84 - $8.56 $29,035 - $36,337	4,245 Added 21.99%	23,548 $161,000
Q1 2023 May 11, 2023	BUY	$6.85 - $13.0 $5,575 - $10,582	814 Added 4.4%	19,303 $140,000
Q4 2022 Feb 14, 2023	BUY	$11.99 - $14.5 $5,083 - $6,148	424 Added 2.35%	18,489 $237,000
Q3 2022 Nov 10, 2022	BUY	$12.03 - $14.22 $12,860 - $15,201	1,069 Added 6.29%	18,065 $255,000
Q2 2022 Aug 11, 2022	BUY	$11.57 - $17.92 $196,643 - $304,568	16,996 New	16,996 $209,000

12.6M

23.8K

Ticker AADI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 21,016,800
Market Cap $48.3M
Description
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, ...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.